Methotrexate Pfizer (Methotrexate)

Methotrexate inhibits the enzyme dihydrofolate reductase, which is required for the synthesis of tetrahydrofolate. This interruption reduces the production of purine nucleotides and thymidylate, essential building blocks for DNA and RNA, thereby limiting the growth of rapidly dividing cells such as immune cells and cancer cells.

The dose of Methotrexate Pfizer is individualized by the prescribing healthcare professional based on the specific indication, patient weight, renal function, and other clinical factors. Only a qualified prescriber can determine the appropriate dosage regimen.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception. Limited data exist for breastfeeding, and the drug may be excreted in milk; therefore, use is generally discouraged unless the benefits outweigh the risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methotrexate belongs to the antimetabolite class, differing from biologic agents that target specific cytokines. It is often less expensive and can be used as monotherapy or in combination with other drugs. However, its safety profile requires regular monitoring of liver function and blood counts, which may be less intensive with some newer agents.

Methotrexate Pfizer should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Maintaining a stable ambient environment helps preserve the tablet’s potency and prevents degradation.

Methotrexate Pfizer is supplied as an oral formulation that is taken by mouth with or without food, as directed by the prescriber. The exact administration schedule—daily, weekly, or as part of a treatment cycle—is determined by the treating physician based on the indication.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to life‑threatening infections, and renal impairment. Patients should be monitored regularly for signs of organ dysfunction, and any concerning symptoms should prompt immediate medical evaluation.

Methotrexate is contraindicated in patients with known hypersensitivity to the drug, those who are pregnant, and individuals with severe liver or renal disease. Caution is also advised for patients with active infections, immunodeficiency, or those taking certain interacting medications.